

ENCAPSULATION PRODUCTS FOR CONTROLLED
OR EXTENDED RELEASE

Encaps

5 BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to an encapsulation process,
and in particular, an alternate encapsulation process for
10 concentrating additives using compression. Also, the present
inventive subject matter relates to encapsulation products that
provide controlled or extended release of actives.

2. Description of the Prior Art

15 Various types of chewable articles are known in commerce.
These articles include food items such as food items,
confectionery items and chewing gum. The chewable articles
often include various types of active agents or ingredients
within the chewable articles. Examples of such active
20 ingredients include flavors, sweeteners, colors, medicaments,
pharmaceuticals, vitamins, minerals, and other effervescent
agents.

It has been known in the art of food stuff, confectionery
and chewing gum preparation to provide protection to the active
25 ingredients by the use of protection systems, including
providing a protective coating around the active ingredient or
encapsulating the active ingredient. Such protective systems
have been employed for various reasons, such as for protection
of the active ingredient, both while on the shelf and during
30 use, and for prolonged release in the oral cavity.

It is known in the art to protect active ingredients by
encapsulating the active ingredient prior to introducing the
ingredient into a final product. Some of the major

classifications of encapsulation technology include liquid suspending media (water-in-oil emulsions and oil-in-water emulsions), interfacial and in situ polymerization, solvent evaporation from emulsions, desolvation, complex coacervation, polymer and polymer incompatibility, gelation, and pressure extrusion. One of skill in the art will be familiar with each of these classifications.

Schobel, U.S. Patent No. 4,568,560, discloses encapsulated fragrances and flavors for use in denture cleanser compositions. Schobel discloses encapsulating a solid particulate flavoring agent or fragrance with a film of an acrylic polymer and ethylcellulose. The encapsulation is accomplished utilizing a fluidized bed of the flavoring agent or fragrance.

Yang, U.S. Patent No. 4,740,376, discloses encapsulating an active ingredient in a solvent free encapsulation composition which includes a blend of a high molecular weight polyvinyl acetate and a hydrophilic plasticizer. The active ingredient is protected from deterioration due to moisture and is provided with controlled release for use in a product to be ingested by a mammal.

Cherukuri et al., U.S. Patent No. 4,981,698, discloses a delivery system for sweeteners that comprises a first high intensity sweetener encapsulated in a first core coating, and a second outer hydrophilic coating containing up to the solubility limit of the second coating of a second sweetener. The delivery system offers enhanced up front sweetness intensity in combination with prolonged sweetness duration, and improved protection and stability of the sweetener.

Cherukuri et al., U.S. Patent No. 5,004,595, discloses a free-flowing particulate delivery system for providing enhanced flavor and sweetness to comestible products. The delivery

system includes an encapsulating matrix that protects flavor in a core.

Cherukuri et al., U.S. Patent No. 5,266,335, discloses microencapsulated flavoring agents and methods for preparing the same. The microencapsule comprises a flavoring agent and a resin in the core, and a coating layer over the core. The core is encapsulated by emulsion of a flavoring agent and a resin with a coating layer prepared by complex coacervation of a mixture of two or more colloidal materials.

Kehoe, U.S. Patent No. 4,975,270, discloses elastomer encased active ingredients. The active ingredients are physically encased in non-porous, chewable particles of elastomer. The particles are then incorporated into articles of commerce.

As is seen above, historically, the most convenient and commonly employed route of drug delivery has been by oral ingestion. The original controlled release of pharmaceuticals was through coated pills which dates back over 1000 years. Coating technology advanced in the mid- to late 1800s with the discovery of gelatin and sugar coatings. A major development in coating technology was the concept of coating drug-containing beads with combinations of fats and waxes. Since the mid-1900s, hundreds of publications and nearly a thousand patents have appeared on various oral delivery approaches encompassing delayed, prolonged, suspended and most recently, controlled release of active ingredients.

In the mid- to late 1960s, the term controlled drug delivery came into being to describe new concepts of dosage form design. These concepts usually involved controlling drug dissolution but also had additional objectives. The primary objectives of a controlled-release system have been to enhance

safety and extend duration of action. Today, controlled-release systems are designed in order to produce more reliable absorption and to improve bioavailability and efficiency of delivery.

5 The overwhelming majority of controlled release systems rely on dissolution, diffusion, or a combination of dissolution and diffusion to generate slow release of a drug. Ueda et al., U.S. Patent No. 4,874,549, disclose a time-controlled system in which a drug is diffused into a patient after the explosion of
10 a membrane at a given period of time after ingestion. The system is comprised of a preparation in the form of a bead or granule which makes up a core, a drug, a swelling agent and an outer membrane made up of a water-insoluble coating material.

15 Chen, U.S. Patent No. 5,508,040, discloses a multiparticulate pulsatile drug delivery system. The system is comprised of a large number of pellets containing a drug and a water soluble osmotic agent. The pellets are an agglomerate of sugar seeds with the drugs spray-coated thereon.

20 Philippon et al., U.S. Patent No. 5,229,135, disclose a sustained release diltiazem formulation. The formulation is ingested orally and, like Chen above, the core is a central sugar sphere with a plurality of coatings in which the drug is adhered to the sphere.

25 Chen, U.S. Patent No. 5,567,441, also discloses a diltiazem controlled release formulation to be ingested orally. And like Chen and Philippon above, the core is a non-pareil or sugar bead on which the drug is applied via a coating.

30 However, there are a number of perceived disadvantages with regards to controlled release of drugs into a system. The disadvantages include a longer time to achieve therapeutic blood concentrations, possible increased variation in bioavailability

after oral administration, enhanced first-pass effect, dose dumping, sustained concentration in overdose cases, lack of dosage flexibility and, often, greater expense. It should be pointed out that there are a number of constraints on the design of oral controlled drug delivery systems: dose size, drug molecular size, charge and pKa, aqueous solubility, partition coefficient, stability, absorption, metabolism, half-life, margin of safety, toxicity, and clinical response.

In addition, there are a number of disadvantages when using the traditional encapsulation processes to encapsulate active ingredients, including pharmaceuticals and nutraceuticals. The disadvantages include the need for heat and moisture in order to properly form the encapsulated final product. Also, most encapsulation methods are complex and consume large amounts of time in order to obtain the final encapsulated product. Further, current encapsulated ingredients vary in size from nanometers to about 400 microns, and the active ingredients are not uniformly distributed throughout the encapsulated product.

Therefore, there remains a need for an alternate encapsulation method for providing a controlled or extended release product with high levels of active ingredients and in which water is not needed during the encapsulation process, nor is heat an essential feature of the encapsulation process. There also remains a need for an alternate encapsulation method which produces capsules with uniform active ingredient content throughout the product, and that can withstand mechanical pressure both in the processing of the capsule and in the chewing of the product in the mouth so that the active ingredients are released in the stomach of the consumer. Further, there remains a need for a simple encapsulated product that provides good controlled and extended release

characteristics for pharmaceuticals.

BRIEF SUMMARY OF THE INVENTION

Applicant has unexpectedly produced an extended or
5 controlled release encapsulated product, comprising:

- a) at least one active ingredient;
- b) at least one erodible polymer; and
- c) at least one lubricating material; and
- d) wherein said product is in the form of a caplet
10 having a diameter from about 1 millimeter to about 7 millimeters
and a length from about 1 millimeter to about 7 millimeters.

In a preferred embodiment of the present inventive subject
matter, the erodible polymer is a water soluble polymer.

In another preferred embodiment, the erodible polymer is a
15 water insoluble polymer.

A further preferred embodiment is drawn to a pulsating
release encapsulated product, comprising:

- a) at least one active ingredient;
- b) at least two erodible polymers, each of said
20 erodible polymers having a different rate of dissolution; and
- c) at least one lubricating material; and
- d) wherein said product is in the form of a caplet
having a diameter from about 1 millimeter to about 7 millimeters
and a length from about 1 millimeter to about 7 millimeters.

25 A still further preferred embodiment is drawn to a
pulsating release product, comprising a capsule having a
plurality of caplets, said caplets comprising:

- a) at least one active ingredient;
- b) at least one erodible polymer;
- 30 c) at least one lubricating material; and
- d) wherein said caplet has a diameter from about 1

millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters; and

wherein at least one of said plurality of caplets is prepared from an erodible polymer having a first dissolution rate, and at least another of said plurality of caplets is prepared from another erodible polymer having a second dissolution rate, and said first dissolution rate is not equal to said second dissolution rate.

An advantage of method of the inventive subject matter is that no heat nor moisture is required for forming the encapsulated product. High levels of active ingredients are obtainable in the products of the inventive subject matter, even though heat or moisture is not required for forming the encapsulated product. In addition, the encapsulated product of the present inventive subject matter has a uniform active ingredient content and may be strong enough to withstand mechanical pressure both in the processing of the product, and in the chewing of the product in the mouth so that the active ingredients are released in the stomach.

DETAILED DESCRIPTION OF THE INVENTION

The encapsulated product of the present invention is a caplet containing a surprisingly high amount of an active ingredient and providing excellent controlled or extended release properties. Applicants have unexpectedly determined that active ingredients can be compressed with high load into a small encapsulated product.

The controlled release products of the present inventive subject matter are designed to produce a sustained concentration of pharmaceutical in the blood. The advantages of the controlled or extended release products of the present inventive

subject matter include reduced toxicity and sustained efficacy of the active ingredients; decreased frequency of dosing, resulting in improved patient compliance, reduced patient care; and possibly reduced amount of drug used.

5 In a preferred embodiment of the present invention, the controlled or extended release encapsulated product of the present inventive subject matter is a caplet shaped like a capsule and having a diameter from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. Preferably, the diameter of the encapsulated product is about 3 millimeters and the length is about 3 millimeters. The caplets may be coated with a thin surface film to protect the product from moisture or water absorption, from flavor release in the final product system, and from heat and rupture during processing and chewing.

As used herein, the expression "mammal" includes without limitation any mammalian subject, such as mice, rats, guinea pigs, cats, dogs, human beings, cows, horses, sheep or other livestock.

20 As used herein, the term "active ingredient" includes without limitation: flavors, sweeteners, herbal ingredients, pharmaceuticals, vitamins, minerals, and mixtures thereof.

As used herein, "controlled release" or "extended release" relates to the release rates of the pharmaceutical from the encapsulated product into the mammal. The terms refer to the release of the drug over a period of time, for example from one hour to twenty-four hours.

Currently, controlled release formulations are generally created through different technological approaches which include:

- Drug loading on spherical pellets, can be accomplished through either solvent based or aqueous coatings.

- Monolithic (tablets) dosage forms based on hydrophillic swelling polymers in which the drug is dispersed and then released through hydrated swollen matrix.
- Erodible matrixes, either multi-particulate or monolithic, that release the included active substance, generally poorly water soluble, by controlled erosion of the system.
- Osmotic systems in monolithic, tablets, form that release the drug, soluble in digestive fluids, through a calibrated hole in the osmotic membrane surrounding the tablet.

In a preferred embodiment, the active ingredient to be released into a mammal is incorporated into an erodible polymer matrix. A general method for preparing a controlled-release encapsulated product encompasses the following steps. First, the active ingredient is mixed with a suitable erodible polymer. The active ingredient may be present in amounts from 0.001 to 70.0% by weight of the final encapsulated product. The erodible polymer may be present from 10.0 to 70.0% by weight of the final encapsulated product.

The present inventive subject matter contemplates that the erodible polymer may be either water soluble or water insoluble. Water soluble polymers useful in the present inventive subject matter include, without limitation, sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, propylene glycol alginate, sodium alginate, carboxymethyl cellulose and mixtures thereof.

Likewise, water insoluble polymers that are useful in the present inventive subject matter include, without limitation, cellulose acetate, ethyl cellulose, cellulose acetate methyl carbamate, methylcarbamate, polydiethylaminomethylstyrene, ethyl cellulose, cellulose acetate, cellulose diacetate, cellulose

triacetate, cellulose alkanylate, monoalkenytes, dialkenytes, trialkenytes, mono-, di- and tri-arylates, cellulose trivalerate, cellulose trioctanoate, cellulose tripionate, cellulose diesters, cellulose disuccinate, cellulose acetate valerate, cellulose acetaldehyde, dimethylcellulose acetate, cellulose dimethylaminoacetate, semipermeable sulfonated polystyrenes, semipermeable styrenes, and mixtures thereof.

The active ingredient/polymer mixture is then granulated using a suitable binder. The binder is generally present in amounts of 1.0 to 10.0% by weight of the final encapsulated product. Binders suitable for use in the present inventive subject matter include, without limitation, plasdone K-29/32, povidone K30, carboxymethylcellulose sodium, ethylcellulose, methylcellulose, alginic acid and mixtures thereof.

After the active ingredient/polymer mixture is granulated, the mixture is passed through a mesh, preferably a mesh no. 10, and allowed to air dry. After air-drying, the mixture is passed through another mesh, preferably a no. 20 mesh.

After passing through the second mesh, the granulated mixture is lubricated with a lubricant and compressed into capsules with the sizes listed above. The lubricant or lubricating material forms a film around the granules and helps the material flow, compress and eject from the tableting machine. The lubricant or lubricating material may be present in levels up to 5% by weight of the final composition. Examples of usable lubricating materials include, without limitation, fats, emulsifiers, waxes, magnesium stearate, calcium stearate, talc, starches, silicon dioxide, and mixtures thereof. Among the fats, or fatty materials, useful herein include, without limitation, water-insoluble, inert hydrocarbon fats or oils, or their derivatives and mixtures thereof. Such fats or fatty

materials include, for example and without limitation, cocoa butter, hydrogenated vegetable tallow, hydrogenated vegetable oils, and derivative mixtures thereof.

Among the emulsifiers useful herein include, without
5 limitation, alkyl aryl sulfonates, alkyl sulfates, sulfonated
amides and amines, sulfated and sulfonated esters and ethers,
alkyl sulfonates, polyethoxylated esters, mono- and
diglycerides, diactyl tartaric esters of monoglyderides,
polyglycerol esters, sorbitan esters and ethoxylates, lactylated
10 esters, propylene glycol esters, sucrose esters and mixtures
thereof. Among the waxes useful herein include, without
limitation, amorphous waxes, anionic emulsifying waxes, bleached
waxes, caranda waxes, cetyl esters, cationic emulsifying waxes,
microcrystalline waxes, paraffins, refined waxes and mixtures
15 thereof.

The use of particular fats, emulsifiers or waxes may allow
the encapsulated product of the present inventive subject matter
to aid in providing controlled or sustained release of the
active ingredient. The controlled release occurs due to the
20 entrapment of the active material in the particular fat,
emulsifier or wax.

It is possible to provide a coating on the encapsulated
product. The coating provides protection of the active
ingredients from moisture or water absorption. The coating may
25 also allow the release of the active ingredient in the stomach
of the individual, and not in the mouth thereof.

In one aspect of the inventive subject matter the
encapsulated product is coated with a polymeric coating to form
an extended release formulation. In this aspect the extended
30 release formulations are where the mechanism of release is
driven, predominantly, by the osmotic pressure.

In the present procedure, the encapsulated products are formulated with osmotic ingredients and coated with semi-permeable film forming polymers to achieve zero-order release. The advantages of this formulation include the combination of the mechanism of the control of the release based on the osmotic pressure (finely tuned and independent from the motility, pH, composition of the digestive fluids and food) with the concept of multiple units (improved inter and intra-subjects variability of absorption).

Active ingredients can be any pharmacologically active substance to be administered by the oral route and included in a solid dosage form.

Osmotic ingredients can be any active principle ingredient with a solubility in aqueous media, in the range of pH from 1 to 7 and in an amount of not less than 0.1%.

Any inorganic salt may be used which is highly dissociated in aqueous media in the range of pH from 1 to 7 and suitable to be included in pharmaceutical preparations for oral administration.

Semi-permeable film forming polymers can be high molecular weight derivatives of cellulose which are insoluble in water as ethylcellulose with a degree of ethylation between 43% and 50%, cellulose acetate with 30%-45% of acetyl value, polyvinylacetate, ammonium methacrylate co-polymers.

Suitable plasticizers can be added in the range of 5% to 35%. The film thickness may vary from 20 μ m to 100 μ m to achieve the desired extended release profile. The size of encapsulated products may vary between 2mm to 3mm of diameter and height. Depending on the composition of the core and on the type and thickness of the film different zero order kinetics can be achieved.

This encapsulated product formulation can be applied to any

controlled release applications including OTC & Rx Pharmaceuticals, and Nutritional applications.

In another aspect of the inventive subject matter, the encapsulated product is coated with a polymeric coating to form a delayed release formulation. In this aspect, the delayed release, monolithic, oral dosage form is based on osmotic pressure and then a crown coating in the coating polymer formed *in situ* when the dose is ingested.

Oral dosage forms have heretofore been generally based on osmotic pressure by preparing a core, usually in the form of a tablet, containing the active substance dispersed in a combination of ingredients able to generate an osmotic pressure, when contained by an osmotic membrane. The release from such systems is obtained with a calibrated hole in the membrane which regulates, together with the level of osmotic pressure generated by the intrinsic characteristics of the tablet core, the rate of release.

In the present invention, tablets with swelling polymers, osmotic ingredients and active substance, with a cone protuberance on one side are then coated with semi-permeable film-forming polymer. The thickness of the film is lower on the cone. By swelling, the film brakes on the cone because the lower thickness and the content of the vesicle (the coated tablet) is released. For given dimensions and composition of the tablet, the time to break is regulated by the thickness of the film and the height of the cone. This system allows to match the result without the need of holing the osmotic film with a laser beam, risk of irradiated polymers with free radicals, or by using a micro drill, a costly process.

Active ingredients can be any pharmacologically active substance to be administered by the oral route and included in

a solid dosage form.

Osmotic ingredients can be any active principle ingredient with a solubility in aqueous media, in the range of pH from 1 to 7 and in amounts not less than 0.1%.

5 Any inorganic salt may be used which is highly dissociated in aqueous media in the range of pH from 1 to 7 and suitable to be included in pharmaceutical preparations for oral administration.

10 Swelling polymers can be polycarbophyls and hydroxypropylmethylcellulose of different viscosity such as from 4,000 to 100,000 cps.

The diameter of the tablets can vary from 5 mm to 10 mm.

The thickness can vary from 3 mm to 5 mm.

The height of the cone can vary from 0.5 mm to 1.0 mm.

15 The shape of the protuberance is conical with the diameter of the base that can vary from 0.8 to 1.3 mm.

20 Semi-permeable film forming polymers can be high molecular weight derivatives of cellulose which are insoluble in water as ethylcellulose with a degree to ethylation between 43% and 50%, cellulose acetate with 30%-45% of acetyl value, polyvinylacetate, ammonium methacrylate co-polymers.

Suitable plasticizers can be added in the range of 5% to 35%. The film thickness may vary from 20 μ m to 150 μ m.

25 This formulation can be applied to any modified release applications including OTC & Rx Pharmaceuticals, and Nutritional applications.

30 In a preferred embodiment of the present inventive subject matter, the controlled release of the encapsulated product provide "pulses" or "pulsating release" of the active ingredients. By "pulses" or "pulsating release", Applicants mean that the active ingredient is released at different time

intervals while in the body of the mammal. By "pulsating," Applicants also mean that the release of the active ingredients may be continuous, discontinuous, extended or sustained. Preferably, the "pulsating" aspect of the release of the active ingredients means the discontinuous release of the actives.

Many active ingredients need frequent administration of burst doses in order to achieve optimal effect of the active ingredient. The most common way of achieving pulsating release of active ingredients has been to coat the drug with slowly dissolving polymeric membranes or with protective polymers that dissolve selectively at pH's corresponding to specific regions of the gastrointestinal tract. Once the polymeric membrane has dissolved, all of the drug inside the membrane is immediately available for dissolution and absorption. Thus, the drug release can be controlled by adjusting the thickness and dissolution rate of the polymeric membrane surrounding the drug. If only a few different thicknesses of membrane are used, the drug will be released at different, predetermined times, or "pulses." The present inventive subject matter contemplates coating the encapsulated products with such polymeric membranes, as is discussed above.

In addition, however, the present inventive subject matter provides pulsating delivery of the active ingredient by taking advantage of the different characteristics of the different the polymer erodible polymers used in the encapsulated products. In a preferred embodiment of the present inventive subject matter, the encapsulated product is prepared with at least two erodible polymers, each having a different rate of dissolution in the body of the mammal in which the encapsulated product is introduced.

For example, the encapsulated product may be made with two

or more erodible polymers, at least one that erodes quickly in the body to provide immediate dissolution of the drug and at least another that does not erode as quickly, thus delaying release of the active ingredient until a desired time.

5 As is stated above, an important aspect of this embodiment of the present inventive subject matter is the incorporation of at least two erodible polymers having different rates of dissolution. The present inventive subject matter contemplates the use of both water soluble polymers and water insoluble
10 polymers for this preferred embodiment. Examples of water soluble and water insoluble polymers are listed above. Depending on the desired characteristics encapsulated product and release profile of the active ingredient, the erodible polymers used to achieve the pulsating release of the active
15 ingredient may be water soluble, water insoluble, or a mixture thereof. One of ordinary skill in the art will be able to easily determine which polymers are suitable to achieve the desired pulsating release of the active ingredients based on the dissolution rates of the various erodible polymers.

20 In a further embodiment of the present inventive subject matter, the pulsating effect is achieved by incorporating into a standard capsule encapsulated products prepared from different erodible polymers. In this embodiment, the active ingredient is incorporated into multiple encapsulated products using two or
25 more different erodible polymers, with each encapsulated product being prepared with a different erodible polymer. Then, the different encapsulated products are included in a standard capsule which is taken by the mammal. The encapsulated products will erode at different rates based upon the erodible polymers
30 with which the products were made, providing a pulsating release profile of the active ingredients. Again one of ordinary skill in the art will be able to easily determine which polymers are

suitable to achieve the desired pulsating release of the active ingredients based on the dissolution rates of the various erodible polymers.

While the above delivery of controlled release encapsulated products is by oral ingestion of the encapsulated products, the present inventive subject matter also contemplates site-specific delivery of the active ingredients by different modes of introduction of the active ingredient into the body. The different modes include, for example, introduction of the encapsulated products rectally, which will allow introduction of the products directly into the large bowel of the mammal. In this way, the encapsulated products will act much like a suppository, providing controlled release of the active ingredients while at the same time by-passing the oral route of delivery.

Another example of a non-oral controlled delivery of active ingredients by the present inventive subject matter is to have the inventive encapsulated products implanted into the body. In this embodiment, the encapsulated products, produced and preserved sterile until use, would be implanted directly into the region of the body where the need for the active ingredient is the greatest. Then, as the bodily fluids erode the erodible polymers of the encapsulated products, the active ingredients would be released directly to the site which needs the active ingredients the most.

A further example of site specific delivery of active ingredients according to the present inventive subject matter is to apply the inventive encapsulated products directly to a cut or abrasion on the skin of the mammal being treated. The size of the inventive encapsulated products allows for direct application to the wound in order to directly deliver the needed

active ingredient. Preferably, the inventive encapsulated products will be held in place with a bandage, thus keeping optimal contact between the encapsulated products and the wound.

In the above non-oral delivery embodiments, the controlled release encapsulated products may have the same characteristics as described above for oral delivery of active ingredients. That is, the controlled release may be zero order, or may provide a pulsating effect, as is defined above. Further, the pulsating effect may be the result of two or more different erodible polymers being incorporated into the same inventive encapsulated product, or the pulsating effect may be due to the presence of multiple encapsulated products having been made from different erodible polymers having different rates of dissolution.

The above non-oral delivery routes of active ingredients are meant as non-limiting examples only, and it should be recognized that other non-oral delivery routes are also within the contemplation of the present inventive subject matter.

The amount of active material present in the inventive compositions will vary depending on the particular active used, but generally will be present in an amount of about 0.001% to 70% by weight of the composition. Preferably, the active ingredients used in the inventive compositions are prophylactic or therapeutic active ingredients. Prophylactic or therapeutic active materials which can be used in the present invention are varied. A non-limiting list of such materials includes the following: antibiotics, antitussives, antihistamines, decongestants, alkaloids, mineral supplements, laxatives, antacids, ion exchange resins, anti-cholesterolemics, antiarrhythmics, antipyretics, analgesics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer

agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, anti-infectives, psycho-tropics, antimanics, stimulants, gastrointestinal agents, sedatives, antidiarrheal preparations, anti-anginal drugs, vasodialators, anti-hypertensive drugs, vasoconstrictors, migraine treatments, antibiotics, tranquilizers, anti-psychotics, antitumor drugs, anticoagulants, antithrombotic drugs, hypontics, anti-emetics, anti-nausants, anti-convulsants, neuromuscular drugs, hyper- and hypoglycemic spasmodics, uterine relaxants, mineral and nutritional additives, antiobesity drugs, anabolic drugs, erythropoetic drugs, antiashmatics, cough suppressants, mucolytics, anti-uricemic drugs and mixtures thereof.

Preferred therapeutic active materials contemplated for use in the present inventive subject matter are analgesics. Examples of analgesics useful in the present inventive subject matter, and which are the preferred therapeutic active ingredients, include, without limitation, aspirin, acetaminophen, ibuprophen and mixtures thereof.

Another preferred active material can be selected from the class of prophylactic, abortive or analgesic drugs used to treat migraines. Migraines are defined as headaches that last 4 to 72 hours wherein the patient experiences moderate to severe cranial throbbing. Migraines are also associated with nausea, vomiting, or sensitivity to light, sound or smell.

For prophylactic treatment of migraines, β -blockers, calcium channel blockers, tricyclic antidepressants, or anticonvulsants can be used. Examples of drugs indicated for prophylactic treatment include amitriptyline, methysergide, popranolol, valproate, and verapamil.

For abortive treatment of migraines serotonin receptor

activators such as eletriptan, ergotamine, naratriptan, rizatriptan benzoate, sumatriptan succinate, and zolmitriptan can be used. Ergot alkaloid derivatives such as ergoamine tartrate and dihydroergotamine are also effective. Dopamine antagonist anti-emetics such as dimenhydrinate, metoclopramide and prochlorperazine, while indicated for the treatment of nausea, can also be used even if nausea is not prominent.

For analgesic treatment acetaminophen, aspirin, non-asteroidal anti-inflammatory drugs ("NSAID") and opioids can be used in the present invention.

In general, any class of drug indicated for migraine treatment may be used in the present invention. For example, sumatriptan succinate may be incorporated into the encapsulated products of the present invention to effectively deliver sumatriptan succinate to a patient in need thereof. In particular, sumatriptan succinate can be formulated with the present invention in doses ranging from 25, 50, to 100 mg daily. All the examples are non-limiting and it will be understood that other migraine therapeutics may be used with the present inventive subject matter.

Yet another preferred active material used in the composition of the present inventive matter is a psychotropic. Psychotropics are used to treat depression, schizophrenia, anxiety disorders, attention deficit order, obsessive compulsive disorder, senile dementia and certain sleep disorders.

The classes of drugs used in treating depression include selective serotonin reuptake inhibitors ("SSRI's"), heterocyclic antidepressants, monoamine oxidase inhibitors ("MAOI's"), serotonergic-noradrenergics, 5-HT₂ antagonists and catecholaminergics. Examples of SSRI'S include fluoxetine HCl, sertraline HCl, paroxetine HCl, and fluvoxamine. Examples

of heterocyclic antidepressants include amitriptyline, nortriptyline, imipramine, desipramine, doxepin, trimipramine, clomipramine, protriptyline, amoxapine, and maprotiline.

Examples of MAOI's include phenelzine and tranylcypromine. An

5 example of a serotonergic-noradrenergics includes venlafaxine HCl. Examples of 5-HT₂ antagonists include trazadone, nefazodone, and mirtazapine. An example of a catecholaminergics

includes bupropion. All examples are non-limiting and it will be understood that psychotropics of the disclosed classes may be

10 used with the present inventive subject matter.

In general, any class of psychotropic drug indicated for treating depression may be used in the present invention. For example, fluoxetine HCl may be incorporated into the encapsulated products of the present invention to effectively
15 deliver fluoxetine HCl to a patient in need thereof. In particular, fluoxetine HCl can be formulated with the present invention in doses ranging from about 10 to 60 mg daily. One of ordinary skill in the art will be able to determine the proper dosage for the remaining disclosed drugs.

20 For the treatment of anxiety, benzodiazepines may be used with the present inventive subject matter. Specific examples include alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, lorazepam, and oxazepam. However, any class of psychotropic drug indicated for anxiety treatment may be used in
25 the present invention.

In particular, alprazolam may be incorporated into the encapsulated products of the present invention to effectively deliver alprazolam to a patient in need thereof. In particular, alprazolam can be formulated with the present invention in doses
30 ranging from about 0.25 to 0.50 mg to be taken three times daily. One of ordinary skill in the art will be able to

determine the proper dosage for the remaining disclosed drugs.

For the treatment of insomnia, drugs belonging to the categories of benzodiazepines, imidazopyridines, antidepressants and non-prescription hypnotics may be used with the present inventive subject matter. Examples of benzodiazepines useful for the treatment of insomnia include midazolam, triazolam, oxazepam, temazepam, lorazepam, estazolam, nitrazepam, diazepam, quazepam, flurazepam, zopiclone and clorazepate. An example of an imidazopyridine includes zolpidem and zolpidem tartarate. Examples of antidepressants include amitriptyline and doxepin.

In particular, zolpidem may be incorporated into the encapsulated products of the present invention to effectively deliver zolpidem to a patient in need thereof. In particular, zolpidem can be formulated with the present invention in doses ranging from about 5.0 to 30.0 mg daily, the preferred range being from about 5.0 to 10.0 mg daily. One of ordinary skill in the art will be able to determine the proper dosage for the remaining disclosed drugs. Moreover, all the examples are non-limiting and it will be understood that other psychotropics may be used with the present inventive subject matter.

Still yet another preferred active material used in the composition of the present inventive matter is a gastrointestinal therapeutic. Gastrointestinal therapeutics are used to treat gastritis, nausea and vomiting, gastroesophageal reflux disease, colitis, Crohn's disease and diarrhea. Classes of drugs include proton pump inhibitors, histamine H₂ receptor antagonists, terpene analogs, and NSAIDs.

For the treatment of gastritis, drugs such as omeprazole, lansoprazole, ranitidine HCl, famotidine, nizatidine, teprenone, cimetidine, rabeprazole sodium, and sulpiride can be used in the compositions of the present inventive subject matter.

For the treatment of nausea and vomiting, drugs such as

ondansetron HCl, granisetron HCl, dolasetron mesylate, and tropisetron may be used.

In particular, omeprazole may be incorporated into the encapsulated products of the present invention to effectively deliver omeprazole to a patient in need thereof. In particular, omeprazole can be formulated with the present invention in doses ranging from about 10.0 to 60.0 mg daily, the preferred range being from about 15.0 to 25.0 mg daily. One of ordinary skill in the art will be able to determine the proper dosage for the remaining disclosed drugs. Moreover, all the examples are non-limiting and it will be understood that other gastrointestinal therapeutics may be used with the present inventive subject matter.

Another preferred active material used in the compositions of the present invention include cardiovascular therapeutics. Cardiovascular therapeutics treat hypertension, angina, myocardial infarction, congestive heart failure, acute coronary syndrome, edema, ventricular tachycardia, hyperaldosteronism, ventricular arrhythmia, cardiac insufficiency, atrial fibrillation, arterial occlusion, cardiac decompensation, and microcirculation activation.

A related class of cardiovascular therapeutics are cholesterol reducers such as 3-hydroxy-3-methylglutaryl coenzymeA ("HMG-CoA") reductase inhibitors. HMG-CoA inhibitors work by blocking an enzyme used to make cholesterol. Blocking cholesterol thereby treats hypercholesterolemia which is a significant cause of cardiovascular disease.

For the treatment of hypercholesterolemia, drugs such as simvastatin, atorvastatin calcium, pravastatin sodium, pravastatin, lovastatin, fluvastatin sodium, cerivastatin sodium can be used in the compositions of the present inventive subject

matter.

For the treatment of hypertension, drugs such as nifedipine, amlodipine besylate, losartan potassium, lisinopril, felodipine, benazepril HCl, ramipril, irbesartan, verapamil HCl, 5 bisoprolol fumarate and hydrochlorothiazide, amlodipine and benazepril HCl, clonidine, candesartan, cilexetil, diltiazem, nicardipine, imidapril, trandolapril, eprosartan mesylate, nilvadipine, verapamil HCl, temocapril, prazosin HCl, 10 isradipine, cilazapril, celiprolol, bisoprolol, betazolol HCl, ramipril, nisoldipine, lisinopril, trandolapril, and nisoldipine can be used in the compositions of the present inventive subject matter.

For the treatment of congestive heart failure, drugs such as dioxin, carvedilol, spironolactone, trandolapril, and 15 bisoprolol can be used in the compositions of the present inventive subject matter.

In particular, simvastatin may be incorporated into the encapsulated products of the present invention to effectively deliver simvastatin to a patient in need thereof. In particular, 20 simvastatin can be formulated with the present invention in doses ranging from about 5.0 to 80 mg daily. One of ordinary skill in the art will be able to determine the proper dosage for the remaining disclosed drugs. Moreover, all the examples are non-limiting and it will be understood that drugs from the disclosed 25 classes may also be used with the present inventive subject matter.

Still another preferred active material used in the composition of the present invention is a therapeutic useful for treating allergic rhinitis. The classes of compounds useful for 30 treating allergic rhinitis include alkylamines, ethanolamines, ethylenediamines, piperazines, phenothiazine, piperdines, and

nonsedating compounds.

Among the non-sedating compounds that can be used in the present invention are loratadine, fexofenadine HCl, certirizine HCl, and astemizole. Other drugs which can also be used are
5 fluticasone propionate, mometasone furoate, epinastine, beclomethasone dipropionate, triamcinolone acetonide, budesonide, and azelastine.

In particular, loratadine may be incorporated into the encapsulated products of the present invention to effectively
10 deliver loratadine to a patient in need thereof. In particular, loratadine can be formulated with the present invention in doses ranging from about 5.0 to 15 mg daily, with 15mg daily being the preferred dosage. One of ordinary skill in the art will be able to determine the proper dosage for the remaining disclosed
5 drugs. Moreover, all the examples are non-limiting and it will be understood that other allergic rhinitis therapeutics may be used with the present inventive subject matter.

Still yet another preferred active material used in the composition of the present invention is a therapeutic useful for
20 treating osteoarthritis or rheumatoid arthritis. Rheumatoid arthritis is defined as non-specific, symmetrical inflammation of the peripheral joints, potentially resulting in progressive destruction of articular and periarticular structures. Osteoarthritis is characterized by loss of articular cartilage
25 and hypertrophy of bone. Although osteoarthritis is a degenerative bone disease, symptoms associated with rheumatoid arthritis such as inflammation of the joints occur in a patient diagnosed with osteoarthritis. Accordingly, therapeutics treating rheumatoid arthritis can also be administered to an
30 osteoarthritic patient.

Classes of drugs indicated for osteoarthritis and

rheumatoid arthritis include cyclooxygenase-2 inhibitors, NSAID'S, biologic response modifiers, pyrimidine synthesis inhibitors and hyaluronic acid. Specific examples of osteoarthritis and rheumatoid arthritis therapeutics include
5 celecoxib, diclofenac sodium, rofecoxib, nabumetone, diclofenac sodium and misoprostol, oxaprozin, meloxicam, piroxicam, etodolac, naproxen, hylan G-F 20, leflunomide, tenoxicam, and naproxen sodium.

In particular, celecoxib may be incorporated into the
10 encapsulated products of the present invention to effectively deliver celecoxib to a patient in need thereof. In particular, celecoxib can be formulated with the present invention in doses ranging from about 150 to 250 mg daily, with 200 mg daily being the preferred dosage. One of ordinary skill in the art will be
15 able to determine the proper dosage for the remaining disclosed drugs. Moreover, all the examples are non-limiting and it will be understood that other osteoarthritis and rheumatoid arthritis therapeutics from the disclosed classes may also be used with the present inventive subject matter.

Another preferred active material used in the composition
20 of the present invention is a therapeutic useful for treating benign prostatic hypertrophy. Benign prostatic hypertrophy is defined as an adenomatous hyperplasia of the periurethral part of the prostate gland.

Classes of drug useful for the treatment of benign
25 prostatic hypertrophy include alpha blockers, alpha-1 selective adrenoceptor blocking agents and 5-reductase inhibitors. Specific examples of benign prostatic hypertrophy therapeutics include doxazosin mesylate, terazosin HCl, tamsulosin,
30 finasteride, tamsulosin HCl, ethinyl estradiol and levonorgestrel.

In particular, doxazosin mesylate may be incorporated into encapsulated products of the present invention to effectively deliver doxazosin mesylate to a patient in need thereof. In particular, doxazosin mesylate can be formulated with the present invention in doses ranging from about 1 to 16 mg daily. One of ordinary skill in the art will be able to determine the proper dosage for the remaining disclosed drugs. Moreover, all the examples are non-limiting and it will be understood that other benign prostatic hypertrophy therapeutics from the disclosed classes may also be used with the present inventive subject matter.

Yet another preferred active material used in the composition of the present invention is a drug indicated for the treatment of fungal infections. Classes of drugs indicated for the treatment of fungal infections include synthetic triazole, ergosterol inhibitor, and polyene antifungal. Specific examples of drugs indicated for the treatment of fungal infections are itraconazole, ketoconazole, and amphotericin B.

In particular, itraconazole may be incorporated into the encapsulated products of the present invention to effectively deliver itraconazole to a patient in need thereof. In particular, itraconazole can be formulated with the present invention in doses ranging from about 1.0 to 400 mg daily. One of ordinary skill in the art will be able to determine the proper dosage for the remaining disclosed drugs. Moreover, all the examples are non-limiting and it will be understood that other anti-fungals from the disclosed classes may also be used with the present inventive subject matter.

Still yet another preferred active material used in the composition of the present invention is a anti-convulsant. Anti-convulsants are drugs that prevent or relieve convulsions

wherein the convulsions are due to epilepsy, seizure disorders, partial seizure disorders or Huntington's disease. Classes of drugs useful for treating these conditions include gamma-aminobutyric analogs, phenyltriazine, antiepileptic agents, benzodiazepines, polysynaptic response inhibitors, sulfamate-substituted monosaccharides, gamma-amino butyric acid uptake inhibitors and benzamides. Specific examples include carbamazepine, topiramate, and tigabine HCl.

In particular, carbamazepine may be incorporated into the encapsulated products of the present invention to effectively deliver carbamazepine to a patient in need thereof. In particular, carbamazepine can be formulated with the present invention in doses ranging from about 100 to 1600 mg daily. One of ordinary skill in the art will be able to determine the proper dosage for the remaining disclosed drugs. Moreover, all the examples are non-limiting and it will be understood that other anti-convulsants from the disclosed classes may also be used with the present inventive subject matter.

Another preferred active material used in the composition of the present invention is an anti-herpetic. Anti-herpetics are used to treat infections from the varicella-zoster virus. Classes of drugs useful for treating herpes include synthetic purine nucleoside analogs, nucleoside analogs, and antiviral agents. Specific examples include acyclovir, valacyclovir HCL and famcyclovir.

In particular, acyclovir may be incorporated into the encapsulated products of the present invention to effectively deliver acyclovir to a patient in need thereof. In particular, acyclovir can be formulated with the present invention in doses ranging from about 200 to 800 mg daily. One of ordinary skill in the art will be able to determine the proper dosage for the

remaining disclosed drugs. Moreover, all the examples are non-limiting and it will be understood that other anti-herpetics from the disclosed classes may also be used with the present inventive subject matter.

5 Yet another active material used in the compositions of the present invention are anti-diarrheal therapeutics. Anti-diarrheal therapeutics treat the condition of diarrhea whether it is symptomatic of the disorder itself wherein diarrhea is a condition that occurs when a mammal has a low amount of stool in
10 a bowel movement. Diarrhea results mainly from excess fecal water in the bowel of the mammal. Specific examples of anti-diarrheal therapeutics include loperamide HCl, diphenoxylate, codeine phosphate, camphorated opium tincture.

In a further embodiment of the present invention, he
15 encapsulated product includes the incorporation of flavors. The flavoring agents which may be used include those flavors known to the skilled artisan, such as natural and artificial flavors. These flavorings may be chosen from synthetic flavor oils and flavoring aromatics and/or oils, oleoresins and extracts derived
20 from plants, leaves, flowers, fruits, and so forth, and combinations thereof. Nonlimiting representative flavor oils include spearmint oil, cinnamon oil, oil of wintergreen (methyl salicylate), peppermint oil, clove oil, bay oil, anise oil, eucalyptus oil, thyme oil, cedar leaf oil, oil of nutmeg,
25 allspice, oil of sage, mace, oil of bitter almonds, and cassia oil. Also useful flavorings are artificial, natural and synthetic fruit flavors such as vanilla, and citrus oils including, without limitation, lemon, orange, lime, grapefruit, and fruit essences including apple, pear, peach, grape,
30 strawberry, raspberry, cherry, plum, pineapple, apricot and so forth. These flavoring agents may be used in liquid or solid

form and may be used individually or in admixture. Commonly used flavors include mints such as peppermint, menthol, artificial vanilla, cinnamon derivatives, and various fruit flavors, whether employed individually or in admixture.

5 Other useful flavorings include aldehydes and esters such as cinnamyl acetate, cinnamaldehyde, citral diethylacetal, dihydrocarvyl acetate, eugenyl formate, p-methylamisol, and so forth may be used.

10 If the flavor to be added is liquid, then the liquid flavor is first absorbed onto a solid absorbent. Examples of absorbents on which the liquid may be absorbed include, without limitation, silica gel particles, starches, carbohydrates such as sugars and polyhydroxyalcohols, celluloses, calcium salts such as calcium phosphate, calcium carbonate, and calcium
15 sulfonate, and other absorbing agents in free-flowing powder form. The amount of liquid flavor added depends on the final concentration desired. Generally, though, the liquid flavor will be present in quantities from about 0.1% to 70% by weight of the resultant flavor/absorbent mixture.

20 The flavor/absorbent mixture is then mixed with a the erodible polymer above.

Furthermore, other additives such as colors, may also be added to this mixture to form the final mixture. The final mixture is then formed into the encapsulated product of the
25 present invention by using a tableting machine. The stations of the tableting machine are set to the desired caplet size, which is from about 1 millimeter to about 7 millimeters diameter and length for the encapsulated.

30 The use of flavor with the active ingredient in the encapsulated product allows for flexibility in adding flavor to food items, confectionery products or chewing gum products. For

example, delivery of two or more flavors to a single food item is possible by using encapsulated products containing different flavors in the food item. The delivery of two or more flavors is also possible in confectionery products and chewing gum products.

Advantages of preparing the inventive encapsulated product in this manner are that no heat and no moisture are needed in this process. Additionally and surprisingly, high concentrations of active ingredients may be incorporated into the final encapsulated product. Furthermore, the encapsulated product of the present inventive subject matter is small enough that when the confectionery or chewing gum product is chewed, the encapsulated product can pass with the saliva and not be disformed by the teeth of the individual chewing.

Examples of vitamins that are available as active ingredients include, without limitation, vitamin A (retinol), vitamin D (cholecalciferol), vitamin E group (α -tocopherol and other tocopherols), vitamin K group (phyllloquinones and menaquinones), thiamine (vitamin B₁), riboflavin (vitamin B₂), niacin, vitamin B₆ group, folic acid, vitamin B₁₂ (cobalamins), biotin, vitamin C (ascorbic acid), and mixtures thereof. The amount of vitamin or vitamins present in the final encapsulated product of the present inventive subject matter is dependent on the particular vitamin and is generally the United States' Department of Agriculture Recommended Daily Allowances (USRDA) for that vitamin. For example, if vitamin C is the active ingredient and the encapsulated product is being used in a confectionery or chewing gum targeting adults, the amount of vitamin C in the encapsulated product would be 60 milligrams, which is the USRDA of vitamin C for adults.

Examples of minerals that are available as active

ingredients include, without limitation, calcium, magnesium, phosphorus, iron, zinc, iodine, selenium, potassium, copper, manganese, molybdenum and mixtures thereof. As is the case with vitamins, the amount of mineral or minerals present in the final encapsulated product of the present inventive subject matter is dependent on the particular mineral and is generally the USRDA for that mineral. For example, if iodine is the active ingredient and the encapsulated product is being used in a confectionery or chewing gum targeting adults, the amount of iodine in the encapsulated product would be 150 micrograms, which is the USRDA of iodine for adults.

Examples of herbals that are available as active ingredients include, without limitation, echinacea, peppermint, licorice, goldenseal, panax pseudoginseng, grapeseed extract, bilberry, kava, ginko biloba, panax quinquefolium, Siberian ginseng, St. John's wort, bromelian, guggulipids, hawthorn, garlic, ginger, angelica species, dandelion, goldenseal, and mixtures thereof. Further, examples of spices that are available as active ingredients include, without limitation, mustard, dillweed, cinnamon, garlic, black pepper, onion, sage, oregano, basil, cream of tartar, targon, cayenne pepper, red pepper, and mixtures thereof. This list of herbals and spices is for exemplary purposes and is not meant to be construed as limiting the inventive subject matter thereto.

As is stated above, an advantage of method of the inventive subject matter is that no heat nor moisture is required for forming the encapsulated product. In addition, the encapsulated product of the present inventive subject matter has a uniform active ingredient content and may be strong enough to withstand mechanical pressure both in the processing of the product, and in the chewing of the product in the mouth so that the active

ingredients are released in the stomach.

The following examples are illustrative of preferred embodiments of the invention and are not to be construed as limiting the invention thereto. All percentages are given in weight percent, unless otherwise noted and equal a total of 100%.

EXAMPLES

10

EXAMPLE 1: Preparation of a 50-mg Capsule of Dimenhydrinate Encapsulated Product

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
220

1. As can be seen, the dissolution rate was zero order for the capsule.

EXAMPLE 2: Preparation of a 30-mg Capsule of Nifedipine

5

34.10% nifedipine was mixed with 10.90% lactose anhydrous, 0.90% microcrystalline cellulose, and 48.90% hydroxypropyl methyl cellulose in a shear mixer. The mixture was then granulated using 4.20% povidone K30 dissolved in isopropyl alcohol. The granulated mixture was passed through a no. 10 mesh and allowed to air dry. When the granulated mixture was dry, it was then passed through a no. 20 mesh. The mixture was next lubricated with 1.00% magnesium stearate. The final mixture was mixed for 3 minutes. The mixture was loaded into a
15 tableting machine.

A series of caplets was produced using 20 KN of force. Each caplet weighed 17.60 mg and five caplets were filled in a no. 2 capsule to obtain a 30-mg nifedipine capsule.

The 30-mg capsule was then tested *in vitro* for dissolution characteristics. The capsule was loaded into a no. 2 apparatus (paddle, USP) with 900 ml of water (phosphate buffer pH: 6.8). The capsule was rotated at 50 rpm (revolutions per minute) and the amount dissolved was determined at 1, 2, 5, 7 and 9 hours
20

The results of the dissolution test are provided in Figure
25 2. As can be seen, the dissolution rate was zero order for the capsule.

EXAMPLE 3: Preparation of a 30-mg Capsule of Nifedipine

30

34.10% nifedipine was mixed with 20.00% lactose anhydrous, 1.00% microcrystalline cellulose, and 38.90% hydroxypropyl

methyl cellulose (19.45% HPMC K15 M and 19.45% HPMC K100 M) in a shear mixer. The mixture was then granulated using 5.00% povidone K30 dissolved in isopropyl alcohol. The granulated mixture was passed through a no. 10 mesh and allowed to air dry.

5 When the granulated mixture was dry, it was then passed through a no. 20 mesh. The mixture was next lubricated with 1.00% magnesium stearate. The final mixture was mixed for 3 minutes. The mixture was loaded into a tableting machine.

10 A series of caplets was produced using 20 KN of force. Each caplet weighed 17.57 mg and five caplets were filled in a no. 2 capsule to obtain a 30-mg nifedipine capsule.

15 The 30-mg capsule was then tested *in vitro* for dissolution characteristics. The capsule was loaded into a no. 2 apparatus (paddle, USP) with 900 ml of water (phosphate buffer pH: 6.8). The capsule was rotated at 50 rpm (revolutions per minute) and the amount dissolved was determined at 1, 2, 5, 7 and 9 hours

20 The results of the dissolution test are provided in Figure 2. As can be seen, the dissolution rate was zero order for the capsule.

EXAMPLE 4: Preparation of a 30-mg Capsule of Nifedipine

25 34.10% nifedipine was mixed with 20.00% lactose anhydrous, 1.00% microcrystalline cellulose, and 38.90% hydroxypropyl methyl cellulose (11.67% HPMC K15 M and 27.23% HPMC K100 M) in a shear mixer. The mixture was then granulated using 5.00% povidone K30 dissolved in isopropyl alcohol. The granulated mixture was passed through a no. 10 mesh and allowed to air dry.

30 When the granulated mixture was dry, it was then passed through a no. 20 mesh. The mixture was next lubricated with 1.00%

magnesium stearate. The final mixture was mixed for 3 minutes. The mixture was loaded into a tableting machine.

5 A series of caplets was produced using 20 KN of force. Each caplet weighed 17.57 mg and five caplets were filled in a no. 2 capsule to obtain a 30-mg nifedipine capsule.

10 The 30-mg capsule was then tested *in vitro* for dissolution characteristics. The capsule was loaded into a no. 2 apparatus (paddle, USP) with 900 ml of water (phosphate buffer pH: 6.8). The capsule was rotated at 50 rpm (revolutions per minute) and the amount dissolved was determined at 1, 2, 5, 7 and 9 hours

The results of the dissolution test are provided in Figure 2. As can be seen, the dissolution rate was zero order for the capsule.

15 Example 5: Preparation of 250-mg Capsule for Pulsating Release of Mesalamine

20 72.5% 5-aminosalicylic acid was mixed with 22.5% HPMC K100 in a shear mixer. The mixture was then granulated using 3.9% povidone K30 dissolved in isopropyl alcohol. The granulated mixture was passed through a no. 10 mesh and allowed to air dry. When the granulated mixture was dry, it was then passed through a no. 20 mesh. The mixture was next lubricated with 1.3% magnesium stearate. The final mixture was mixed for 3 minutes. 25 The mixture was loaded into a tableting machine.

30 A series of caplets was produced using 20 KN of force. Each caplet weighed 23.00 mg. Six of the caplets were coated using a film coating comprising 70% cellulose acetate phthalate as a film forming agent and 30% triethylcitrate as a plasticizer. At the same time, 9 caplets were coated using a film coating comprising 70% eudragit RS as a film forming agent

and 30% dibutylphtalate as a plasticizer. The fifteen coated caplets were filled in a size 0 capsule to obtain a 250-mg mesalamine capsule.

5 Example 6: Preparation of 300-mg Capsule for Pulsating
 Release of Clindamycin Hydrochloride

87.0% clindamycin hydrochloride was mixed with 7.8% microcrystalline cellulose in a shear mixer. The mixture was
10 then granulated using 3.9% povidone K30 dissolved in isopropyl alcohol. The granulated mixture was passed through a no. 10 mesh and allowed to air dry. When the granulated mixture was dry, it was then passed through a no. 20 mesh. The mixture was next lubricated with 1.3% magnesium stearate. The final mixture
15 was mixed for 3 minutes. The mixture was loaded into a tableting machine.

A series of caplets was produced using 20 KN of force. Each caplet weighed 23.00 mg. Seven of the caplets were coated using a film coating comprising 70% cellulose acetate phtalate as a film forming agent and 30% triethylcitrate as a
20 plasticizer. At the same time, eight caplets were coated using a film coating comprising 70% HPC as a film forming agent and 30% dibutylphtalate as a plasticizer. The fifteen coated caplets were filled in a size 0 capsule to obtain a 300-mg
25 clindamycin hydrochloride capsule.

The inventive subject matter being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit
30 and scope of the inventive subject matter, and all such modifications are intended to be included within the scope of the following claims.